Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals

Objectives: The AHA/ACC-2017 hypertension guideline recommends an age-independent target blood pressure (BP) of less than 130/80 mmHg. In an elderly cohort without established cardiovascular disease (CVD) at baseline, we determined the impact of this guideline on the prevalence of hypertension and a...

Full description

Bibliographic Details
Main Authors: Chowdhury, Enayet, Ernst, M.E., Nelson, M., Margolis, K., Beilin, L.J., Johnston, C., Woods, R., Murray, A., Wolfe, R., Storey, E., Shah, R.C., Lockery, J., Tonkin, A., Newman, A., Abhayaratna, W., Stocks, N., Fitzgerald, S., Orchard, S., Trevaks, R., Donnan, G., Grimm, R., McNeil, J., Reid, Christopher
Format: Journal Article
Language:English
Published: LIPPINCOTT WILLIAMS & WILKINS 2020
Subjects:
Online Access:https://europepmc.org/article/PMC/8218338
http://hdl.handle.net/20.500.11937/93110
_version_ 1848765700476239872
author Chowdhury, Enayet
Ernst, M.E.
Nelson, M.
Margolis, K.
Beilin, L.J.
Johnston, C.
Woods, R.
Murray, A.
Wolfe, R.
Storey, E.
Shah, R.C.
Lockery, J.
Tonkin, A.
Newman, A.
Abhayaratna, W.
Stocks, N.
Fitzgerald, S.
Orchard, S.
Trevaks, R.
Donnan, G.
Grimm, R.
McNeil, J.
Reid, Christopher
author_facet Chowdhury, Enayet
Ernst, M.E.
Nelson, M.
Margolis, K.
Beilin, L.J.
Johnston, C.
Woods, R.
Murray, A.
Wolfe, R.
Storey, E.
Shah, R.C.
Lockery, J.
Tonkin, A.
Newman, A.
Abhayaratna, W.
Stocks, N.
Fitzgerald, S.
Orchard, S.
Trevaks, R.
Donnan, G.
Grimm, R.
McNeil, J.
Reid, Christopher
author_sort Chowdhury, Enayet
building Curtin Institutional Repository
collection Online Access
description Objectives: The AHA/ACC-2017 hypertension guideline recommends an age-independent target blood pressure (BP) of less than 130/80 mmHg. In an elderly cohort without established cardiovascular disease (CVD) at baseline, we determined the impact of this guideline on the prevalence of hypertension and associated CVD risk. Methods: Nineteen thousand, one hundred and fourteen participants aged at least 65 years from the ASPirin in Reducing Events in the Elderly (ASPREE) study were grouped by baseline BP: 'pre-2017 hypertensive' (BP <140/90mmHg and/or on antihypertensive drugs); 'reclassified hypertensive' (normotensive by pre-2017 guidelines; hypertensive by AHA/ACC-2017 guideline), and 'normotensive' (BP <130 and <80 mmHg). For each group, we evaluated CVD risk factors, predicted 10-year CVD risk using the Atherosclerotic Cardiovascular Disease (ASCVD) risk equation, and reported observed CVD event rates during a median 4.7-year follow-up. Results: Overall, 74.4% (14 213/19 114) were 'pre-2017 hypertensive'; an additional 12.3% (2354/19 114) were 'reclassified hypertensive' by the AHA/ACC-2017 guideline. Of those 'reclassified hypertensive', the majority (94.5%) met criteria for antihypertensive treatment although 29% had no other traditional CVD risk factors other than age. Further, a relatively lower mean 10-year predicted CVD risk (18% versus 26%, P<0.001) and lower CVD rates (8.9 versus 12.1/1000 person-years, P=0.01) were observed in 'reclassified hypertensive' compared with 'pre-2017 hypertensive'. Compared with 'normotensive', a hazard ratio (95% confidence interval) for CVD events of 1.60 (1.26-2.02) for 'pre-2017 hypertensive' and 1.26 (0.93-1.71) for 'reclassified hypertensive' was observed. Conclusion: Applying current CVD risk calculators in the elderly 'reclassified hypertensive', as a result of shifting the BP threshold lower, increases eligibility for antihypertensive treatment but documented CVD rates remain lower than hypertensive patients defined by pre2017 BP thresholds.
first_indexed 2025-11-14T11:39:25Z
format Journal Article
id curtin-20.500.11937-93110
institution Curtin University Malaysia
institution_category Local University
language English
last_indexed 2025-11-14T11:39:25Z
publishDate 2020
publisher LIPPINCOTT WILLIAMS & WILKINS
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-931102024-01-18T10:12:41Z Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals Chowdhury, Enayet Ernst, M.E. Nelson, M. Margolis, K. Beilin, L.J. Johnston, C. Woods, R. Murray, A. Wolfe, R. Storey, E. Shah, R.C. Lockery, J. Tonkin, A. Newman, A. Abhayaratna, W. Stocks, N. Fitzgerald, S. Orchard, S. Trevaks, R. Donnan, G. Grimm, R. McNeil, J. Reid, Christopher Science & Technology Life Sciences & Biomedicine Peripheral Vascular Disease Cardiovascular System & Cardiology elderly guidelines hypertension target blood pressure CARDIOVASCULAR RISK TASK-FORCE Aged Aged, 80 and over Antihypertensive Agents Blood Pressure Cohort Studies Female Heart Disease Risk Factors Humans Hypertension Male Practice Guidelines as Topic ASPREE Investigator Group Humans Hypertension Antihypertensive Agents Cohort Studies Blood Pressure Aged Aged, 80 and over Female Male Practice Guidelines as Topic Heart Disease Risk Factors Objectives: The AHA/ACC-2017 hypertension guideline recommends an age-independent target blood pressure (BP) of less than 130/80 mmHg. In an elderly cohort without established cardiovascular disease (CVD) at baseline, we determined the impact of this guideline on the prevalence of hypertension and associated CVD risk. Methods: Nineteen thousand, one hundred and fourteen participants aged at least 65 years from the ASPirin in Reducing Events in the Elderly (ASPREE) study were grouped by baseline BP: 'pre-2017 hypertensive' (BP <140/90mmHg and/or on antihypertensive drugs); 'reclassified hypertensive' (normotensive by pre-2017 guidelines; hypertensive by AHA/ACC-2017 guideline), and 'normotensive' (BP <130 and <80 mmHg). For each group, we evaluated CVD risk factors, predicted 10-year CVD risk using the Atherosclerotic Cardiovascular Disease (ASCVD) risk equation, and reported observed CVD event rates during a median 4.7-year follow-up. Results: Overall, 74.4% (14 213/19 114) were 'pre-2017 hypertensive'; an additional 12.3% (2354/19 114) were 'reclassified hypertensive' by the AHA/ACC-2017 guideline. Of those 'reclassified hypertensive', the majority (94.5%) met criteria for antihypertensive treatment although 29% had no other traditional CVD risk factors other than age. Further, a relatively lower mean 10-year predicted CVD risk (18% versus 26%, P<0.001) and lower CVD rates (8.9 versus 12.1/1000 person-years, P=0.01) were observed in 'reclassified hypertensive' compared with 'pre-2017 hypertensive'. Compared with 'normotensive', a hazard ratio (95% confidence interval) for CVD events of 1.60 (1.26-2.02) for 'pre-2017 hypertensive' and 1.26 (0.93-1.71) for 'reclassified hypertensive' was observed. Conclusion: Applying current CVD risk calculators in the elderly 'reclassified hypertensive', as a result of shifting the BP threshold lower, increases eligibility for antihypertensive treatment but documented CVD rates remain lower than hypertensive patients defined by pre2017 BP thresholds. 2020 Journal Article http://hdl.handle.net/20.500.11937/93110 10.1097/HJH.0000000000002582 English https://europepmc.org/article/PMC/8218338 http://purl.org/au-research/grants/nhmrc/1111170 LIPPINCOTT WILLIAMS & WILKINS unknown
spellingShingle Science & Technology
Life Sciences & Biomedicine
Peripheral Vascular Disease
Cardiovascular System & Cardiology
elderly
guidelines
hypertension
target blood pressure
CARDIOVASCULAR RISK
TASK-FORCE
Aged
Aged, 80 and over
Antihypertensive Agents
Blood Pressure
Cohort Studies
Female
Heart Disease Risk Factors
Humans
Hypertension
Male
Practice Guidelines as Topic
ASPREE Investigator Group
Humans
Hypertension
Antihypertensive Agents
Cohort Studies
Blood Pressure
Aged
Aged, 80 and over
Female
Male
Practice Guidelines as Topic
Heart Disease Risk Factors
Chowdhury, Enayet
Ernst, M.E.
Nelson, M.
Margolis, K.
Beilin, L.J.
Johnston, C.
Woods, R.
Murray, A.
Wolfe, R.
Storey, E.
Shah, R.C.
Lockery, J.
Tonkin, A.
Newman, A.
Abhayaratna, W.
Stocks, N.
Fitzgerald, S.
Orchard, S.
Trevaks, R.
Donnan, G.
Grimm, R.
McNeil, J.
Reid, Christopher
Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
title Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
title_full Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
title_fullStr Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
title_full_unstemmed Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
title_short Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
title_sort impact of the 2017 americanheart association and american college of cardiology hypertension guideline in aged individuals
topic Science & Technology
Life Sciences & Biomedicine
Peripheral Vascular Disease
Cardiovascular System & Cardiology
elderly
guidelines
hypertension
target blood pressure
CARDIOVASCULAR RISK
TASK-FORCE
Aged
Aged, 80 and over
Antihypertensive Agents
Blood Pressure
Cohort Studies
Female
Heart Disease Risk Factors
Humans
Hypertension
Male
Practice Guidelines as Topic
ASPREE Investigator Group
Humans
Hypertension
Antihypertensive Agents
Cohort Studies
Blood Pressure
Aged
Aged, 80 and over
Female
Male
Practice Guidelines as Topic
Heart Disease Risk Factors
url https://europepmc.org/article/PMC/8218338
https://europepmc.org/article/PMC/8218338
http://hdl.handle.net/20.500.11937/93110